Trinity biotech announces amended credit agreement with perceptive to enhance liquidity and drive transformation plan

Dublin, dec. 24, 2024 (globe newswire) -- trinity biotech plc (nasdaq: trib), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has entered into amended agreements with its primary lender, perceptive advisors. these strategic amendments provide additional liquidity, further enhancing the company's near-term financial position as it advances its comprehensive transformation plan and continues development of its innovative continuous glucose monitoring (cgm) technology.
TRIB Ratings Summary
TRIB Quant Ranking